Tiziana Life Sciences is trading 5.15% down at $0.92, with no new negative company-specific announcement identified to explain the decline.
- Shares rose 25.96% to $0.97 on September 17.
- The gain followed a non-binding MOU with KAIMRC and the Foundation for Neurologic Diseases supporting a planned multiple-sclerosis trial evaluating intranasal foralumab.
- Broader biotechnology performance remains positive.